INVA Quote, Financials, Valuation and Earnings

Keros Therapeutics, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -51.05%. Innoviva, Inc.'s return on equity of 17.06% beat Keros Therapeutics, Inc.'s return on equity of 9.94%.

Innoviva, Inc. has a consensus price target of $33.00, signalling upside risk potential of 39.59%. On the other hand Keros Therapeutics, Inc. has an analysts' consensus of $23.00 which suggests that it could grow by 38.97%. Given that Innoviva, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Innoviva, Inc. is more attractive than Keros Therapeutics, Inc..

Innoviva, Inc. has a beta of 0.437, which suggesting that the stock is 56.321% less volatile than S&P 500. In comparison Keros Therapeutics, Inc. has a beta of 0.857, suggesting its less volatile than the S&P 500 by 14.332%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Keros Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Keros Therapeutics, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Keros Therapeutics, Inc. quarterly revenues of $14.3M. Innoviva, Inc.'s net income of $89.9M is higher than Keros Therapeutics, Inc.'s net income of -$7.3M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 16.96x while Keros Therapeutics, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.65x versus 2.73x for Keros Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -301.29%. Innoviva, Inc.'s return on equity of 17.06% beat Nektar Therapeutics's return on equity of -327.67%.

Innoviva, Inc. has a consensus price target of $33.00, signalling upside risk potential of 39.59%. On the other hand Nektar Therapeutics has an analysts' consensus of $123.43 which suggests that it could grow by 68.66%. Given that Nektar Therapeutics has higher upside potential than Innoviva, Inc., analysts believe Nektar Therapeutics is more attractive than Innoviva, Inc..

Innoviva, Inc. has a beta of 0.437, which suggesting that the stock is 56.321% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.341, suggesting its more volatile than the S&P 500 by 34.126%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Innoviva, Inc.'s net income of $89.9M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 16.96x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.65x versus 75.46x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of -382.1%. Innoviva, Inc.'s return on equity of 17.06% beat Oramed Pharmaceuticals, Inc.'s return on equity of 27.49%.

Innoviva, Inc. has a consensus price target of $33.00, signalling upside risk potential of 39.59%. On the other hand Oramed Pharmaceuticals, Inc. has an analysts' consensus of $3.25 which suggests that it could fall by -1.52%. Given that Innoviva, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Oramed Pharmaceuticals, Inc..

Innoviva, Inc. has a beta of 0.437, which suggesting that the stock is 56.321% less volatile than S&P 500. In comparison Oramed Pharmaceuticals, Inc. has a beta of 1.342, suggesting its more volatile than the S&P 500 by 34.249%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals, Inc. offers a yield of 7.58% to investors and pays a quarterly dividend of $0.25 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Oramed Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Oramed Pharmaceuticals, Inc. quarterly revenues of --. Innoviva, Inc.'s net income of $89.9M is higher than Oramed Pharmaceuticals, Inc.'s net income of $48.4M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 16.96x while Oramed Pharmaceuticals, Inc.'s PE ratio is 3.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.65x versus 68.69x for Oramed Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of 80.81% compared to Innoviva, Inc.'s net margin of 18.08%. Innoviva, Inc.'s return on equity of 17.06% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Innoviva, Inc. has a consensus price target of $33.00, signalling upside risk potential of 39.59%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 39.36%. Given that Innoviva, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Innoviva, Inc. is more attractive than Theravance Biopharma, Inc..

Innoviva, Inc. has a beta of 0.437, which suggesting that the stock is 56.321% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.148, suggesting its less volatile than the S&P 500 by 85.221%.

Innoviva, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innoviva, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Innoviva, Inc. quarterly revenues are $111.3M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Innoviva, Inc.'s net income of $89.9M is higher than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Innoviva, Inc.'s price-to-earnings ratio is 16.96x while Theravance Biopharma, Inc.'s PE ratio is 34.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innoviva, Inc. is 4.65x versus 12.03x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.